Featured Methods

Flow Cytometry

Medpace has an experienced flow cytometry team overseen by PhD-level scientists with over 10 years of experience designing, analyzing, and interpreting multicolor flow cytometry assays. Whether a custom panel needs to be developed or a method needs to be transferred to our laboratory to support a global clinical trial, we have the experience to quickly validate and implement the flow cytometry testing.

Medpace has global flow cytometry capabilities at the US, Belgium, and Singapore laboratories.

Central Lab Services include:

Key Instrumentation includes:

• BD FACSCanto™ – 10 Color

Medpace has a strategic lab partnership that has extensive experience performing flow cytometry hematomalignancies, LAIP (leukemia-associated immunophenotypes), and MRD (minimal residual disease) analysis requiring a pathologist review and interpretation.

Preparative Ultracentrifugation (PUC)

Preparative ultracentrifugation (PUC) is the gold standard method for lipoprotein fractionation. Medpace labs is the “go-to” lab for PUC analysis for drugs in development, with capability for this very specialized and technically difficult testing in all four Medpace global central lab locations for low density lipoprotein and other lipoprotein classes. Medpace performs PUC in high volume with over 2,000 analyses monthly.

PUC testing isolates the following lipoproteins, allowing the quantification of cholesterol, triglycerides, apolipoproteins (AI, AII, AIV, B48, B100, CII, CIII, E), phospholipids, fatty acids, and other lipid specific analytes. Lipoprotein fractions isolated include:

• Chylomicron Fraction
• VLDL (Very Low Density Lipoprotein) Fraction
• IDL (Intermediate Density Lipoprotein) Fraction
• LDL(Low Density Lipoprotein) Fraction
• HDL (High Density Lipoprotein) Fraction
• HDL Sub-fractions HDL2 and HDL3

Learn more about PUC from scientific posters presented by Medpace:

Friedewald Formula Significantly Underestimates LDL Cholesterol Compared to Preparative Ultracentrifugation below 70 mg/dL leading to Overestimation of the LDL Cholesterol Reduction for New drugs in Development

Accurate Assessment of LDL Cholesterol Reduction at Levels Below 70mg/dL Has Implications in the Estimation of Efficacy for New Drugs in Development

Underestimation of LDL Cholesterol Below 70 mg/dL (1.8 mmol/L) by Friedewald, Hopkins and a “Direct” Assay Compared to Preparative Ultracentrifugation Leading to the Overestimation of LDL Cholesterol Reduction for New Drugs in Development

LDL Cholesterol Reduction with BMS-962476, An Adnectin Inhibitor Of PCSK9: Results Of A Single Ascending Dose Study